The Community of Madrid opens new avenues in less toxic medications against colon cancer and Crohn's disease
The Community of Madrid opens new avenues in the design of medications for the treatment of gastrointestinal diseases such as colon cancer and Crohn's disease. The Madrid Institute of Advanced Studies (IMDEA) Food works on the analysis of molecules in the human intestine using a machine learning model that allows the development of drugs and food supplements with lower levels of toxicity for the body by acting locally.
This study by the Biostatistics and Bioinformatics Unit, led by Dr. Gonzalo Colmenarejo, has resulted in the creation of a cheminformatics model that facilitates the design of molecules capable of modulating the functioning of metabolites - the substances produced by the organism - and the microbiota present in multiple critical biological processes. These components appear altered in patients with ulcerative colitis, Crohn's disease, diverticulitis or colon cancer.
Using cheminformatics and data science tools, researchers have analyzed nearly 6.000 intestinal substances and linked them to a database of 1.400 oral drugs that are distributed through the bloodstream and reach the entire body. In this way, they have found very different structural and physicochemical patterns that, when applied to new molecules, would allow their side effects to be reduced if they remained in the intestine.